[Drug-induced pulmonary diseases: diagnostic, therapeutic and prognostic aspects. Apropos of 10 personal case reports].
The authors report ten cases of drug induced lung diseases, complicated by respiratory failure of whom five were attributed to cytotoxic drugs and five to non cytotoxic drugs. The drug induced lung disease presented as acute respiratory distress syndrome in two cases, alveolar interstitial lung disease in three cases, purely interstitial in five cases. There was acute respiratory failure (ARF) in eight cases and chronic respiratory failure (CRF) in two cases. Among the five patients admitted for cytotoxic drug induced lung disease and ARF, four recovered and one died of diffuse destructive pulmonary fibrosis. Among the five patients having non cytotoxic drug induced lung disease, three were in ARF and recovered. The other two had CRF and died of diffuse pulmonary fibrosis. The diagnostic of drug induced lung disease was established in each case with the chronology of the clinical events, the exclusion of other possible causes of the lung disease and the evolution after removal of the incriminated drug. Broncho-alveolar lavage (BAL) had a major diagnostic value. It was contraindicated by respiratory failure in five cases. The predominant alveolar cell type was lymphocyte (four cases), eosinophil (three cases) and neutrophil (one case), BAL was realized with a provocation test and demonstrated the pathogenic role of cyclothiazide in one case. No specific information was given by histology. The prognosis did not seem to be linked to the severity of the initial clinical picture, or to the nature of the underlying neoplastic disorder, but to the degree and evolution of the pulmonary fibrosis.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects; D000667:Ampicillin / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D001581:Benzothiadiazines / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D001992:Bronchoalveolar Lavage Fluid; D003520:Cyclophosphamide / Q000009:adverse effects; D004232:Diuretics; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D010672:Phenytoin / Q000009:adverse effects; D011379:Prognosis; D049993:Sodium Chloride Symporter Inhibitors / Q000009:adverse effects; D013467:Sulindac / Q000009:adverse effects; D013839:Thiamphenicol / Q000009:adverse effects
D000305:Adrenal Cortex Hormones; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D001761:Bleomycin; D013467:Sulindac; D010672:Phenytoin; D000667:Ampicillin; D003520:Cyclophosphamide; D013839:Thiamphenicol; D000638:Amiodarone; C004639:cyclothiazide; D008727:Methotrexate
Pneumopathies médicamenteuses. Modalités diagnostiques, thérapeutiques et pronostiques. A propos de 10 observations personnelles.